An April 2021 study of health professionals who developed adverse reactions after a vial of CoronaVac was broken was published in Karger on 27 October 2021. The health personnel exposed to the evaporated vial contents suffered ocular surface erosion and skin rashes.
“Proximity and timing suggest CoronaVac correlation with the ocular and skin reactions. Cautions should be taken to avoid broken vials, spills, and aerosolisation of CoronaVac during the vaccination,” the study authors suggested, “we recommend caution during vaccine handling and fastidious clean-up of any spills.”
Karger, an ophthalmology journal, is dedicated exclusively to case reports. It is a peer-reviewed, open-access journal publishing original case reports covering the entire spectrum of ophthalmology.
A campaign of CoronaVac vaccinations was deployed at Rajavithi Hospital, Thailand, for three days during which a total of 2,296 people were vaccinated.
CoronaVac (Sinovac Biotech, Beijing, China) is a vaccine made of beta-propiolactone inactivated SARS-CoV-2 virus particles with an aluminum hydroxide adjuvant. Its has an efficacy rate of 50.4% for preventing symptomatic infection, according to data from a Brazilian trial, and an effectiveness of 67%, according to a real-world study in Chile.
On 1 June 2021, the World Health Organisation (“WHO”) authorised the Sinovac-CoronaVac Covid-19 vaccine for emergency use. WHO’s Emergency Use Listing (EUL) assesses the quality, safety and efficacy of Covid-19 vaccines.
“WHO’s Strategic Advisory Group of Experts on Immunisation (SAGE) has also completed its review of the vaccine. On the basis of available evidence, WHO recommends the vaccine for use in adults 18 years and older, in a two-dose schedule with a spacing of two to four weeks,” WHO’s EUL announcement stated.
Read More: Vaccinators Have Adverse Reactions to Spilt Contents from Covid “Vaccine” Vial